Vol. 24/No. 14

Emerging data in the neoadjuvant setting and the expansion of testing in standard practice have presented questions surrounding screening for and developing strategies from variant information in EGFR-mutated resectable non–small cell lung cancer.

Luciano J. Costa, MD, PhD, discussed extended follow-up data from the trial and explained how the results may affect frontline treatment decisions in multiple myeloma.

Detection of circulating tumor cells, which are released from primary or metastatic lesions into the bloodstream and are the “seeds” for distant metastatic lesions, has been of interest in cancer research and treatment because these cells can potentially provide information on cancer detection, prognosis, and likelihood of treatment response with minimally invasive methods.

Adult T-cell leukemia/lymphoma is a rare and very aggressive T-cell neoplasm with an extremely poor prognosis. It is also the only human cancer caused by a retrovirus—human T-cell leukemia virus.

Findings from a cross-institutional study suggest that on-pathway regimens led to significant cost savings for patients with cancer, despite the rate of hospitalizations and immune-related adverse events being similar between on-pathway and off-pathway regimens.

Several articles featured in a recent issue of the highly respected publication the Medical Letter on Drugs and Therapeutics highlight themes across drug development that are relevant within the broad antineoplastic arena. The topics range from appropriate control arms in randomized clinical trials to sponsorship of trials to the rationale for developing novel agents when suitable, cost-effective biosimilar and generic products are available.